ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

(2022) Steven R. Ytterberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort

(2022) Adrian Ciurea et al.   RMD Open

Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France

(2022) Maxime Dougados et al.   RMD Open

Implementation of recommendations in rheumatic and musculoskeletal diseases: considerations for development and uptake

(2022) Estibaliz Loza et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

(2022) Augusta Ortolan et al.   ANNALS OF THE RHEUMATIC DISEASES

Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis

(2021) Sizheng Steven Zhao et al.   RHEUMATOLOGY

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

(2021) Atul Deodhar et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial

(2021) Anna Molto et al.   ANNALS OF THE RHEUMATIC DISEASES

2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis

(2021) Elena Nikiphorou et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis

(2021) György Nagy et al.   ANNALS OF THE RHEUMATIC DISEASES

POS1473-HPR SELF- AND SHARED-MANAGEMENT INTERVENTIONS FOR CHILDREN, YOUNG PEOPLE, AND FAMILIES LIVING WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES: AN INTEGRATIVE REVIEW

(2021) S. Stones   ANNALS OF THE RHEUMATIC DISEASES

Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?

(2021) Ulf Lindström et al.   ANNALS OF THE RHEUMATIC DISEASES

The ASAS-OMERACT core domain set for axial spondyloarthritis

(2021) V. Navarro-Compán et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Upadacitinib in Active Ankylosing Spondylitis: 1‐Year Results From the Double‐Blind, Placebo‐Controlled SELECT‐AXIS 1 Study and Open‐Label Extension

(2021) Atul Deodhar et al.   Arthritis & Rheumatology

Axial spondyloarthritis

(2021) Victoria Navarro-Compán et al.   ANNALS OF THE RHEUMATIC DISEASES

What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts

(2020) Alexandre Sepriano et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis

(2020) Alexandre Sepriano et al.   ANNALS OF THE RHEUMATIC DISEASES

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

(2020) Désirée van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

(2020) Iain B McInnes et al.   LANCET

Efficacy of needle-knife combined with etanercept treatment regarding disease activity and hip joint function in ankylosing spondylitis patients with hip joint involvement

(2020) Yuquan You et al.   MEDICINE

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update

(2020) Laure Gossec et al.   ANNALS OF THE RHEUMATIC DISEASES

Determinants of the patient global assessment of well-being in early axial spondyloarthritis: 5-year longitudinal data from the DESIR cohort

(2020) Fumio Hirano et al.   RHEUMATOLOGY

Do smoking and socioeconomic factors influence imaging outcomes in axial spondyloarthritis? Five‐year data from the DESIR cohort

(2020) Elena Nikiphorou et al.   Arthritis & Rheumatology

Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis

(2020) Sizheng Steven Zhao et al.   RHEUMATOLOGY

Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS

(2020) Sizheng Steven Zhao et al.   RHEUMATOLOGY

Peripheral manifestations in spondyloarthritis and their impact: an ancillary analysis of the ASAS-COMOSPA study.

(2019) Clementina López-Medina et al.   JOURNAL OF RHEUMATOLOGY

Comorbidity burden in axial spondyloarthritis: a cluster analysis

(2019) Sizheng Steven Zhao et al.   RHEUMATOLOGY

Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States

(2019) Sizheng Steven Zhao et al.   RHEUMATOLOGY

Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts

(2019) Anne Boel et al.   ANNALS OF THE RHEUMATIC DISEASES

Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis

(2019) Fabian Proft et al.   JOINT BONE SPINE

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

(2019) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

(2019) Michael M. Ward et al.   Arthritis & Rheumatology

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis

(2019) Uta Kiltz et al.   ANNALS OF THE RHEUMATIC DISEASES

Moxibustion therapy in Chinese patients with ankylosing spondylitis: A randomized controlled pilot trial

(2019) Hong-Yuan Wang et al.   European Journal of Integrative Medicine

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

(2019) Désirée van der Heijde et al.   LANCET

EULAR recommendations for the health professional’s approach to pain management in inflammatory arthritis and osteoarthritis

(2018) Rinie Geenen et al.   ANNALS OF THE RHEUMATIC DISEASES

2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis

(2018) Anne-Kathrin Rausch Osthoff et al.   ANNALS OF THE RHEUMATIC DISEASES

Overdiagnosis and overtreatment in rheumatology: a little caution is in order

(2018) Robert B M Landewé   ANNALS OF THE RHEUMATIC DISEASES

Adherence to recommendations for the use of anti–tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis

(2018) Clementina López-Medina et al.   RHEUMATOLOGY

Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GO-EASY Study

(2018) Rianne E. van Bentum et al.   JOURNAL OF RHEUMATOLOGY

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

(2018) Désirée van der Heijde et al.   LANCET

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor

(2018) Atul Deodhar et al.   Arthritis & Rheumatology

Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study

(2016) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study

(2016) Jürgen Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

The term ‘non-radiographic axial spondyloarthritis’ is much more important to classify than to diagnose patients with axial spondyloarthritis

(2016) Atul Deodhar et al.   ANNALS OF THE RHEUMATIC DISEASES

High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort

(2016) Denis Poddubnyy et al.   ANNALS OF THE RHEUMATIC DISEASES

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies

(2016) Omoniyi J. Adedokun et al.   Journal of Crohns & Colitis

Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review

(2016) Victoria Navarro-Compán et al.   RHEUMATOLOGY

Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist

(2016) Christina Charles-Schoeman et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis

(2016) M. Rudwaleit et al.   ARTHRITIS CARE & RESEARCH

Rate and Predisposing Factors for Sacroiliac Joint Radiographic Progression After a Two-Year Follow-up Period in Recent-Onset Spondyloarthritis

(2016) Maxime Dougados et al.   Arthritis & Rheumatology

Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)

(2015) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort

(2015) Victoria Navarro-Compán et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for patient education for people with inflammatory arthritis

(2015) Heidi A Zangi et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice

(2015) P Mandl et al.   ANNALS OF THE RHEUMATIC DISEASES

Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial

(2015) M. Yates et al.   JOURNAL OF RHEUMATOLOGY

A Randomized, Double-Blind, Placebo-Controlled, Sixteen-Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis

(2015) J. Sieper et al.   Arthritis & Rheumatology

Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib

(2015) Christina Charles-Schoeman et al.   Arthritis & Rheumatology

Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS

(2014) U Kiltz et al.   ANNALS OF THE RHEUMATIC DISEASES

Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort

(2014) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations

(2014) Désirée van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab Significantly Reduces the Recurrence Rate of Anterior Uveitis in Patients with Ankylosing Spondylitis

(2014) J. C. van Denderen et al.   JOURNAL OF RHEUMATOLOGY

Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Maxime Dougados et al.   Arthritis & Rheumatology

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

(2013) R Landewé et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial

(2013) H Haibel et al.   ANNALS OF THE RHEUMATIC DISEASES

Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis

(2013) Carmen Stolwijk et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1

(2013) J Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study

(2013) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials

(2013) Andrew D. Dick et al.   OPHTHALMOLOGY

The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study

(2012) U Kiltz et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)

(2012) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor

(2012) Pedro Machado et al.   ANNALS OF THE RHEUMATIC DISEASES

Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis

(2012) Féline Kroon et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort

(2012) Denis Poddubnyy et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis

(2012) Rosaline van den Berg et al.   RHEUMATOLOGY

Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative

(2012) S. L. Whittle et al.   RHEUMATOLOGY

Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria

(2012) K. M. Fagerli et al.   RHEUMATOLOGY

Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis

(2012) Xenofon Baraliakos et al.   RHEUMATOLOGY

A stratified model for health outcomes in ankylosing spondylitis

(2011) P. Machado et al.   ANNALS OF THE RHEUMATIC DISEASES

Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study

(2011) Astrid van Tubergen et al.   ANNALS OF THE RHEUMATIC DISEASES

Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort

(2011) Ho Yin Chung et al.   ANNALS OF THE RHEUMATIC DISEASES

Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis

(2011) Denis Poddubnyy et al.   ARTHRITIS AND RHEUMATISM

Patient preferences for shared decisions: A systematic review

(2011) Betty Chewning et al.   PATIENT EDUCATION AND COUNSELING

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study

(2011) Suzanne Arends et al.   ARTHRITIS RESEARCH & THERAPY

ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis

(2010) M. Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

(2010) P. Machado et al.   ANNALS OF THE RHEUMATIC DISEASES

Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry

(2010) B. Glintborg et al.   ANNALS OF THE RHEUMATIC DISEASES

Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register

(2010) E. Lie et al.   ANNALS OF THE RHEUMATIC DISEASES

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

(2009) M Rudwaleit et al.   ANNALS OF THE RHEUMATIC DISEASES

Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials

(2009) J Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery

(2009) Bert Vander Cruyssen et al.   RHEUMATOLOGY

Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis

(2008) C Lukas et al.   ANNALS OF THE RHEUMATIC DISEASES

Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine

(2008) R Landewe et al.   ANNALS OF THE RHEUMATIC DISEASES

ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis

(2008) D van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Spinal fractures in patients with ankylosing spinal disorders: a systematic review of the literature on treatment, neurological status and complications

(2008) L. A. Westerveld et al.   EUROPEAN SPINE JOURNAL